John W. Rogers Jr.
Ariel Appreciation Fund
John W. Rogers Jr. Bio-Rad Laboratories Inc stake
total: 73
Ariel Appreciation Fund BIO trades
- Total transactions:
- 10
- New positions:
- 1
- Added:
- 5
- Reduced:
- 4
- Held since:
- 2024 Q1
- Held for:
- 10 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, John W. Rogers Jr. holds 76,300 Bio-Rad Laboratories Inc (BIO) shares with a market value of roughly $22.40M accounting for 2.33% of the overall portfolio. To date, the estimated cost basis is nearly $309.71 for "buy" trades and estimated average "sell" price is $291.85. Ariel Appreciation Fund first purchased BIO in 2024 Q1, initially acquiring 34,165 shares. Since the initial investment in Bio-Rad Laboratories Inc (BIO), Ariel Appreciation Fund has made 9 more transactions.
When did John W. Rogers Jr. buy Bio-Rad Laboratories Inc (BIO)?
John W. Rogers Jr. first invested in Bio-Rad Laboratories Inc (BIO) in 2024 Q1 at the reported quarter-end price of $345.87 per share.
What's the cost basis of Ariel Appreciation Fund's BIO stake?
The estimated cost basis for Bio-Rad Laboratories Inc (BIO) stake is around $309.71 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $309.71
- Weighted AVG sell price:
- $291.85
John W. Rogers Jr.'s historical trades in Bio-Rad Laboratories Inc
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
2.33%
|
76,300
|
$293.61
|
$22,402,443
|
-5.69% (-4,600)
|
-0.15%
|
|
2026 Q1
|
2.58%
|
80,900
|
$278.75
|
$22,550,875
|
-3.41% (-2,856)
|
-0.09%
|
|
2025 Q4
|
2.85%
|
83,756
|
$302.99
|
$25,377,230
|
-6.77% (-6,086)
|
-0.21%
|
|
2025 Q3
|
2.81%
|
89,842
|
$280.39
|
$25,190,798
|
-3.61% (-3,363)
|
-0.11%
|
|
2025 Q2
|
2.65%
|
93,205
|
$241.32
|
$22,492,231
|
+6.64% (+5,801)
|
+0.17%
|
|
2025 Q1
|
2.50%
|
87,404
|
$243.56
|
$21,288,118
|
+14.83% (+11,287)
|
+0.32%
|
|
2024 Q4
|
2.62%
|
76,117
|
$328.51
|
$25,005,196
|
+14.05% (+9,379)
|
+0.32%
|
|
2024 Q3
|
2.21%
|
66,738
|
$334.58
|
$22,329,200
|
+29.05% (+15,025)
|
+0.5%
|
|
2024 Q2
|
1.47%
|
51,713
|
$273.11
|
$14,123,337
|
+51.36% (+17,548)
|
+0.5%
|
|
2024 Q1
|
1.10%
|
34,165
|
$345.87
|
$11,816,649
|
new
|
+1.1%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.